Company intelligence / Profile preview

Tutela Pharmaceuticals Inc.

Illinois, United Statestutelapharma.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Tutela Pharmaceuticals Inc. is a nonprofit focused on ensuring continued and affordable access to single-source marketed pharmaceuticals at risk of discontinuation. Its lead program, FK1706, an orally bioavailable small molecule targeting FKBP, was licensed from Astellas after completion of Phase 2 trials for neuropathy. The company aims to develop this asset further for coronavirus infections in combination with antivirals such as remdesivir based on promising in vitro synergy.[3][6] No new clinical results have been published since the license agreement.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

FK1706

Unknown

Partnerships

Astellas Pharma Inc. (exclusive worldwide license for FK1706)

Beyond the preview

Go deeper on Tutela Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tutela Pharmaceuticals Inc..

Explore the full profile